Generating Robust Insights to Develop a Compelling Value Story with RWE

Home / Intelligence / Webinars / Generating Robust Insights to Develop a Compelling Value Story with RWE

Available On Demand

The unprecedented availability of rich RWE data sources gives HEOR, Value and Access and Medical leaders the opportunity to be more intentional than ever before. High-quality, compelling evidence is now a necessity, not just for high-value therapies playing in the rare disease space—but also more broadly, to show reduced unmet needs, health care resource utilization (HCRU) and cost offsets.

Deep experience using industry-leading data sources, tech-enabled methodologies and therapeutic expertise allow Trinity experts to choose the right data for each client situation and create foundational analyses today that will continue to support your questions in the future and drive downstream publications.

Key Webinar Topics

  • Which data sources have the greatest utility for each specific therapeutic area and type of asset?
  • How—and when—can they be leveraged pre- and post-launch?
  • How should disparate data sources be linked/combined to maximize insights?
  • How can ROI be maximized on data acquisition and RWE insights?

Featuring


Complete the form below to view the on-demand webinar.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.

This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.

Related Intelligence

Blog

Rise with the waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future

Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system. The 2024 PLFSS emphasizes: The direct access scheme is expected […]

 Read More

Webinars

2023 NRDL Update: An Ongoing Voyage of Innovation and Accessibility

May 1, 2024 | 12:00 – 12:45 PM ET / 18:00 – 18:45 CET

An additional session will be offered on May 7th at 16:00-16:45 (UTC+8:00) – Asia/Shanghai How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL? As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for […]

 Sign Up Now

Blog

RWE + PMR = Tethering Demand Forecasts to Reality

Reliable forecast models are a cornerstone of any successful commercialization plan. The inputs that drive those forecast models are critical. From 2020 through 2022: Only 1 in 10 products had performance aligned with forecasted expectations* Nearly 60% underperformed their forecast expectations More than 30% overperformed Forecast models often rely on healthcare professional (HCP)-reported behavioral data. […]

 Read More